Basilea and Astellas shake hands on antifungal deal worth up to CHF550 million
24 February 2010
Christopher Spillane
Please Login to read the full article.
24 February 2010
Christopher Spillane
Swiss biotech company Basilea Pharmaceutica has agreed a worldwide licensing deal with Astellas Pharma for its Phase III antifungal isavuconazole.
Basilea will receive CHF75 million ($69.4 million) up front and up to CHF478 million in development and sales milestones as well as...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Austerity takes off gloss from Basilea's Toctino forecasts
- India's 'lopsided' duty structure feeding the Chinese dragon?
- Mixed Indian budget cuts duties on selected pharma products but industry disappointed overall
- Altacor to evaluate lead compound from Proximagen's 5HT2c programme for glaucoma
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
